# BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct07946107` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07946107](<https://clinicaltrials.gov/study/NCT07946107>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07946107

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07946107. Randomized; quadruple masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07946107, source copy `cardio:ctgov-nct07946107-2026-11-18`, retrieved 2026-11-18)
- Planned start: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07946107, source copy `cardio:ctgov-nct07946107-2026-11-18`, retrieved 2026-11-18)
- Primary completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07946107, source copy `cardio:ctgov-nct07946107-2026-11-18`, retrieved 2026-11-18)
- Completion: 2030-01 (anticipated) (ClinicalTrials.gov record NCT07946107, source copy `cardio:ctgov-nct07946107-2026-11-18`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07946107-2026-11-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
- Acronym: NOBLEHEART-HCM
- Condition: Cardiomyopathy, Hypertrophic Non-Obstructive
- Intervention (Drug): BHB-1893
- Intervention (Other): Placebo
- Lead sponsor: Braveheart Bio, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 7bc647fdfd48e9063b81c5f514f83e74c0be2a5ff793cf9754781599dd161043
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
